Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. Issue 3 (June 2016)

• Record Type: Journal Article
• Authors: Samson, Susan L.; Garber, Alan J.
• Is Part Of: Best practice & research. Volume 30:Issue 3(2016)
• Page Start: 357
• Page End: 371
• Publication Date: 2016-06
• Subjects: type 2 diabetes -- weight loss -- obesity -- impaired glucose tolerance -- impaired fasting glucose -- diabetes prevention; HOMA-IR Homeostasis Model assessment-Insulin Resistance -- HOMA-β% Homeostasis Model Assessment-β-cell function -- SGLT2 Sodium-glucose co-transporter 2 -- T2DM Type 2 Diabetes Mellitus; Endocrine glands -- Diseases -- Periodicals; Metabolism -- Disorders -- Periodicals; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1016/j.beem.2016.06.005
• Languages: English
• ISSNs: 1521-690X

Abstract

Abstract : People with impaired glucose tolerance or impaired fasting glucose, or "pre-diabetes", are at high risk for progression to type 2 diabetes, as are those with metabolic syndrome or a history of gestational diabetes. Both glucose-lowering and anti-obesity pharmacotherapies have been studied to determine if the onset of type 2 diabetes can be delayed or prevented. Here we review the available data in the field. The most common theme is the reduction in insulin resistance, such as with weight loss, decreasing demands on the beta cell to improve insulin secretion and prolong its function. Overall, therapies which decrease diabetes incidence in high-risk populations delay the onset of diabetes but do not correct the underlying beta cell defect.